Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Oncoimmunology|May 8, 2015
Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapyJonathan Fisher, Anne-Marijn Kramer, Kenth Gustafsson, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 15, 2026
Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell TherapyMaria T Kuipers, Jorne Migchelbrink, Anne Marijn Kramer, et al.
Oncoimmunology|April 9, 2016
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndromeAstrid Olsnes Kittang, Shahram Kordasti, Kristoffer Evebø Sand, et al.
Blood Cancer Discovery|December 18, 2025
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeHrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, et al.
Lancet (London, England)|July 12, 2024
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 studyMatthew J Frank, John H Baird, Anne Marijn Kramer, et al.
Cancer Discovery|January 8, 2025
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCLYi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, et al.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Cytotherapy|November 5, 2025
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategiesAlexandra Dreyzin, Anne Marijn Kramer, Bonnie Yates, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Nature Medicine|September 4, 2019
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CARSara Ghorashian, Anne Marijn Kramer, Shimobi Onuoha, et al.
Pageof 1